CBUS vs GNS.L
CBUS: Cibus is a gene-editing biotechnology company that licenses proprietary agricultural productivity traits and develops sustainable plant-based ingredients for the global seed and consumer markets. GNS.L: A global leader in animal genetics, using biotechnology to improve the quality and efficiency of livestock production.
Side-by-side fundamentals
| Metric | CBUS | GNS.L | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $1.81 | £22.10 | |
| Market cap as of 2026-08-06 | $146M | n/a | |
| Net margin as of 2026-08-06 | -2366.3% | n/a | |
| Gross margin as of 2026-08-06 | +100.0% | n/a | |
| Operating margin as of 2026-08-06 | -1588.4% | n/a | |
| ROE as of 2026-08-06 | -225.6% | n/a | |
| ROA as of 2026-08-06 | -31.1% | n/a | |
| Debt / equity as of 2026-08-06 | 6.89 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | -9.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +185.1% | n/a | |
| Beta as of 2026-08-06 | 1.68 | n/a | |
| 1-year return as of 2026-07-27 close | +12.4% | -11.2% | CBUS higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.